Biogen (BIIB) Change in Accured Expenses (2016 - 2025)
Historic Change in Accured Expenses for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$215.3 million.
- Biogen's Change in Accured Expenses fell 12783.07% to -$215.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$248.0 million, marking a year-over-year decrease of 3878.01%. This contributed to the annual value of -$248.0 million for FY2025, which is 3878.01% down from last year.
- Per Biogen's latest filing, its Change in Accured Expenses stood at -$215.3 million for Q4 2025, which was down 12783.07% from $286.0 million recorded in Q3 2025.
- In the past 5 years, Biogen's Change in Accured Expenses ranged from a high of $1.1 billion in Q2 2022 and a low of -$745.7 million during Q4 2022
- Moreover, its 5-year median value for Change in Accured Expenses was -$36.6 million (2021), whereas its average is -$44.3 million.
- As far as peak fluctuations go, Biogen's Change in Accured Expenses crashed by 85475.71% in 2022, and later soared by 2486470.59% in 2023.
- Over the past 5 years, Biogen's Change in Accured Expenses (Quarter) stood at $98.8 million in 2021, then plummeted by 854.76% to -$745.7 million in 2022, then surged by 33.55% to -$495.5 million in 2023, then skyrocketed by 80.93% to -$94.5 million in 2024, then plummeted by 127.83% to -$215.3 million in 2025.
- Its last three reported values are -$215.3 million in Q4 2025, $286.0 million for Q3 2025, and -$18.2 million during Q2 2025.